Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has taken a significant step in safeguarding its commercial brand for its lead abuse-deterrent fentanyl transdermal system. The company announced that it received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) on September 2, concerning trademark applications for the product's commercial brand name. This development is crucial as it moves the company closer to securing exclusive rights to the brand identity under which it will market the product.
The Notice of Publication indicates that the USPTO has accepted the trademark applications and will publish them in the Trademark Official Gazette. Following this publication, there is a 30-day opposition period during which third parties may challenge the trademarks. If no objections are raised, the USPTO is expected to issue a Notice of Allowance, paving the way for final registration. This process is a standard but essential step in establishing a strong market presence, as it protects the brand from potential infringement and ensures that the product can be marketed without confusion in the marketplace.
The product at the center of this advancement is a fentanyl patch that incorporates Nutriband's AVERSA™ abuse-deterrent technology. This technology is designed to deter abuse and misuse of fentanyl, a potent opioid, and also aims to reduce the risk of accidental exposure, which is a significant concern with transdermal systems. The company believes that this product has substantial commercial potential, with estimated peak annual U.S. sales ranging from $80 million to $200 million. This projection underscores the importance of the product not only to the company's growth but also to public health efforts to combat opioid abuse.
The intellectual property surrounding the AVERSA™ technology is robust, with patents issued in 46 countries. This global protection is vital for the company's international expansion and for preventing unauthorized use of its proprietary technology. By securing trademarks for the brand name, Nutriband is adding another layer of protection to its commercial assets, which is critical for maintaining a competitive edge and maximizing the product's market potential.
This announcement is significant for investors and stakeholders as it indicates that Nutriband is progressing along the regulatory and legal pathways necessary for product commercialization. The company's focus on abuse-deterrent technologies aligns with broader industry and regulatory trends that emphasize the development of safer opioid formulations. As the opioid crisis continues to challenge public health systems, products that can mitigate abuse potential while still providing effective pain management are in high demand.
The next milestones for Nutriband will be the successful completion of the opposition period and the subsequent receipt of the Notice of Allowance. These steps will bring the company closer to launching its product, which could significantly impact its financial performance and market position. Moreover, the company's commitment to protecting its intellectual property, both patents and trademarks, demonstrates a strategic approach to building a sustainable business in the pharmaceutical sector.
For more information, the full press release is available at https://ibn.fm/p1wVE. Additional updates on Nutriband can be found in the company's newsroom at https://ibn.fm/NTRB.
